Matching articles for "Entocort"
Issue 1610 · November 2, 2020 Free
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease

An oral extended-release formulation of the corticosteroid budesonide ( Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending…

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):176
An oral extended-release formulation of the corticosteroid budesonide ( Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon in patients ≥8 years old and for maintenance of remission for up to 3 months in adults. Ortikos is the second oral formulation of budesonide to be approved for this indication; Entocort EC , an ileal-release formulation, was the first. A third oral formulation of budesonide (Uceris) is approved for induction of remission in patients with mild to moderate active ulcerative colitis.
Issue 1550 · July 2, 2018
Drugs for Inflammatory Bowel Disease

Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Issue 1550 · July 2, 2018
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View Expanded Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e117-22
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Issue 1481 · November 9, 2015
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis

The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC)…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):154
The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris ) for use in patients with UC and as oral enteric-coated tablets ( Entocort EC , and generics) for treatment of Crohn's disease.
Issue 1448 · August 4, 2014
Drugs for Inflammatory Bowel Disease

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is…

Med Lett Drugs Ther. 2014 Aug 4; 56(1448):65-72
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol , Asacol HD , Lialda , and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine ( Azulfidine , and generics), balsalazide ( Colazal , and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa , and generics) and as a rectal suppository (Canasa) .